Maxigen Biotech (TPE:1783) Moat Score: 0/10 (As of Jul. 08, 2026)


TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.70
GF Value NT$61.18
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Moat Score?

Maxigen Biotech has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Maxigen Biotech has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Maxigen Biotech might have No Moat - No discernible moat.

Maxigen Biotech  (TPE:1783) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Maxigen Biotech Moat Score Related Terms

TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.70 is trading 33.5% below its estimated GF Value™ of NT$61.18. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Moat Score: 0
  • GF Value™: NT$61.18 vs. price of NT$40.70 (33.5% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.70
Price
NT$61.18
GF Value